NOS2 and pulmonary hypertension: Our untested hypothesis is that the improvement in vasoconstriction is linked to a balanced activity of NOS isoforms and a reduction in oxidative stress such as demonstrated in a model of pulmonary hypertension treated with a β3-AR agonist [33].